Testosterone Undecanoate (Oral): Comprehensive Research Overview

Document Version: 1.0 Last Updated: December 2024 Classification: Research Paper - Hormone Replacement Therapy (Male HRT)

Goal Relevance:

• Boost energy levels and combat fatigue associated with low testosterone
• Improve libido and enhance sexual wellness for men experiencing low sex drive
• Support muscle growth and strength gains in men with testosterone deficiency
• Assist with hormone optimization for men undergoing testosterone replacement therapy
• Enhance mood and mental clarity for men with low testosterone levels
• Aid in the management of symptoms related to hypogonadism, such as low energy and decreased muscle mass

1. Executive Summary + Regulatory Classification

Overview

Oral testosterone undecanoate (TU) represents a revolutionary advancement in testosterone replacement therapy, being the first oral testosterone formulation approved by the FDA in over 60 years that avoids hepatotoxicity. Unlike earlier 17α-alkylated oral androgens (methyltestosterone), testosterone undecanoate is absorbed via the intestinal lymphatic system, bypassing first-pass hepatic metabolism and avoiding liver damage.

Chemical Name: Testosterone undecanoate (4-androsten-17β-ol-3-one 17-undecanoate) CAS Number: 5949-44-0 Molecular Formula: C₃₀H₄₈O₃ Molecular Weight: 456.71 g/mol

Primary Indications

• FDA-Approved Use: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary hypogonadism [congenital or acquired] and hypogonadotropic hypogonadism [congenital or acquired])

FDA-Approved Oral Testosterone Undecanoate Products

Andriol (original oral TU) was approved in over 80 countries starting in the late 1970s but was never approved in the United States due to significant food-dependency issues and inability to achieve consistent eugonadal testosterone levels.

Regulatory Classification

Key Advantages

• No hepatotoxicity: Unlike methyltestosterone, oral TU shows no liver toxicity
• Lymphatic absorption: Bypasses first-pass metabolism via intestinal lymphatics
• Twice-daily dosing: More convenient than multiple daily doses required by older formulations
• High efficacy: 87-96% of patients achieve eugonadal testosterone levels
• Reversible: Discontinuation results in rapid testosterone decline (unlike long-acting injectables)

Key Disadvantages

• Food requirement: Must be taken with meals containing at least 19g fat
• Twice-daily dosing: Less convenient than weekly injections or daily gel
• Blood pressure elevation: FDA black box warning for increased blood pressure
• Cost: Expensive compared to generic injectables ($150-2400 vs $30-150/month)

2. Chemical Structure & Pharmacology

Molecular Structure

Testosterone undecanoate is an esterified derivative of testosterone, where the 17β-hydroxyl group is esterified with undecanoic acid (11-carbon fatty acid).

Testosterone: C₁₉H₂₈O₂ (288.42 g/mol) + Undecanoic acid (C₁₁H₂₂O₂) → Testosterone undecanoate: C₃₀H₄₈O₃ (456.71 g/mol)

The long aliphatic side chain (11-carbon undecanoate ester) makes testosterone undecanoate highly lipophilic, enabling lymphatic absorption.

Formulation Composition

Jatenzo

Available strengths: 158 mg, 198 mg, 237 mg softgel capsules

Inactive ingredients:

• Oleic acid
• Polyoxyl 40 hydrogenated castor oil (Cremophor RH 40)
• Borage seed oil
• Peppermint oil
• Butylated hydroxytoluene (BHT)

Technology: Self-emulsifying drug delivery system (SEDDS) that forms microemulsions in the gastrointestinal tract

Tlando

Available strengths: 112.5 mg, 150 mg, 200 mg, 225 mg softgel capsules

Inactive ingredients:

• Ascorbyl palmitate
• Glyceryl monolinoleate
• Polyethylene glycol 8000
• Polyoxyl 40 hydrogenated castor oil

Technology: Lip'ral lipid-based formulation designed to maximize lymphatic absorption

Kyzatrex

Available strengths: 100 mg, 150 mg, 200 mg softgel capsules

Technology: Formulated with phytosterols to maximize lymphatic absorption and minimize liver toxicity

Castor Oil Precaution

All testosterone undecanoate formulations contain castor oil derivatives and should not be used if allergic or sensitive to castor oil.

3. Mechanism of Action (Tissue-Specific)

Lymphatic Absorption: The Key Differentiator

Testosterone undecanoate is primarily absorbed (>97%) via the intestinal lymphatic system, a mechanism that distinguishes it from all other oral testosterone preparations.

Absorption pathway:

1. Lipid-based formulation: TU dissolved in lipidic excipients
2. Intestinal lymphatic uptake: Due to long aliphatic side chain (11-carbon ester), TU is incorporated into chylomicrons formed in enterocytes
3. Thoracic duct delivery: Chylomicrons enter systemic circulation via thoracic duct, bypassing portal vein
4. Hepatic first-pass avoidance: TU reaches peripheral circulation before encountering liver, avoiding extensive metabolism

Contrast with 17α-alkylated steroids (methyltestosterone):

• Methyltestosterone is directly transported to liver through portal vein, causing hepatotoxicity
• Oral TU avoids this route entirely

Food Dependency and Chylomicron Formation

When taken with a meal, TU molecules are included in chylomicrons, allowing significant lymphatic absorption. TU is not absorbed under fasting conditions but requires food containing moderate amounts of fat (at least 19g).

Impact of dietary fat:

• 2.1-2.4× higher serum testosterone in fed state (30% fat meal) vs fasting
• 6.2× higher serum TU concentrations in fed state vs fasting

Conversion to Testosterone

Once in circulation, testosterone undecanoate is hydrolyzed by esterases to release free testosterone and undecanoic acid. Testosterone then exerts effects through androgen receptor (AR) binding and tissue-specific metabolism to DHT (via 5α-reductase) and estradiol (via aromatase).

Tissue-Specific Effects

Direct testosterone action:

• Muscle tissue (anabolic effects, protein synthesis)
• Bone (increased bone mineral density)
• Brain (mood, cognition, libido, aggression)
• Adipose tissue (lipolysis, reduced visceral fat)
• Erythropoiesis (red blood cell production)

5α-Reductase conversion to DHT (2.5× more potent):

• Prostate (growth and secretory function)
• Skin (sebaceous gland activity, acne)
• Hair follicles (androgenic alopecia pattern, body/facial hair growth)
• External genitalia

Aromatase conversion to estradiol:

• Bone (epiphyseal closure, bone density maintenance)
• Brain (neuroprotection, mood regulation, libido)
• Adipose tissue
• Breast tissue (gynecomastia at supraphysiological levels)

4. Pharmacokinetics & Formulation Comparison

Absorption

Lymphatic absorption route:

• >97% absorbed via intestinal lymphatic system
• 90-100% transported lymphatically
• Bioavailability: 3-7% when taken with food (low absolute bioavailability, but acceptable given lymphatic route)

Food effect (CRITICAL): Food consumption has critical impact on absorption. Must be taken with food containing at least moderate/normal amount of fat (minimum 19g).

Decreased testosterone exposure observed when administered without food.

Time to Peak Concentration

Oral administration results in peak concentration (Tmax) between 4-5 hours after dosing.

Elimination Half-Life

The elimination half-life of testosterone undecanoate is approximately 2 hours (range: 1.6-2.0 hours), with mean residence time of 3.7 hours.

Clinical implication: Short half-life necessitates twice-daily (BID) or three-times-daily (TID) dosing (80-160 mg/day total for older Andriol formulations; 316-792 mg/day for newer SEDDS formulations).

Steady State

Due to short half-life and BID dosing, steady state is achieved within 1-2 days of initiating therapy.

Interindividual Variability

Very high interindividual variability in testosterone levels with oral TU, influenced by:

• Dietary fat intake with each dose
• Lymphatic absorption capacity
• Individual pharmacokinetics

Distribution

Protein binding: 98% bound to SHBG (40-50%) and albumin (48-58%) Free testosterone: 2% (bioactive fraction) Volume of distribution: Approximately 1.0 L/kg

Metabolism

Primary metabolites:

• Dihydrotestosterone (DHT): via 5α-reductase
• Estradiol (E2): via aromatase (CYP19A1)
• Androsterone and etiocholanolone: inactive metabolites

Excretion:

• Urine: 90% as glucuronide and sulfate conjugates
• Feces: 6%

Formulation Comparison: Jatenzo vs Tlando vs Kyzatrex

Key difference: Main difference is cost. Kyzatrex costs $179 regardless of strength, while Jatenzo ranges $900-2400.

5. Clinical Dosing Guidelines (FDA-Labeled + Off-Label)

Jatenzo Dosing Protocol

Starting dose: 237 mg taken orally twice daily (once in morning, once in evening)

Administration: Take with food

Titration schedule:

• Measure serum testosterone 6 hours after morning dose at Day 7 and Day 14
• Wait 7 days after starting treatment or adjusting dose before checking testosterone
• Dose adjusted on Days 14 and 56 based on 24-hour average testosterone concentration

Dose range:

• Minimum: 158 mg BID (one 158 mg capsule twice daily)
• Maximum: 396 mg BID (two 198 mg capsules twice daily)

Available dose adjustments: 158 mg, 198 mg, 237 mg, 316 mg (158+158), 396 mg (198+198) BID

Target testosterone: 300-1000 ng/dL (eugonadal range)

Tlando Dosing Protocol

Starting dose: 225 mg taken orally twice daily

Administration: Take with food

Titration: Based on predose morning total testosterone concentration

Dose range: 112.5 mg to 450 mg twice daily

Kyzatrex Dosing Protocol

Starting dose: 200 mg taken orally twice daily

Titration: All patients started on 200 mg BID, then titrated to 100 mg, 150 mg, 200 mg, 300 mg, or 400 mg BID to achieve eugonadal range

Efficacy: 87.8% of participants achieved eugonadal mean plasma testosterone; 96.1% of 90-day completers achieved eugonadal levels

Dietary Fat Requirements

Minimum fat requirement: At least 19g fat per meal for adequate absorption

Optimal fat content: 30% fat in meal produces 2.1-2.4× higher testosterone levels vs fasting

Fat sources:

• Oleic acid (olive oil, avocado): Formulation carrier, enhances lymphatic absorption
• Omega-3 fatty acids: May enhance testosterone absorption; DHA supplementation increased total testosterone in overweight/obese men

Monitoring and Timing of Testosterone Measurement

Jatenzo:

• Measure testosterone 6 hours after morning dose
• Wait 7 days after dose adjustment before checking levels
• Evaluate at 4-6 hours post-dose to determine dose adjustment

Timing rationale: Testosterone levels peak 4-5 hours post-dose, so mid-morning measurement (6 hours after morning dose) captures near-peak levels.

Off-Label Dosing: Gender-Affirming Hormone Therapy

Oral testosterone undecanoate is not commonly used for gender-affirming therapy due to cost and BID dosing inconvenience. Injectable testosterone (cypionate/enanthate) or transdermal gel remain preferred for masculinizing therapy.

6. Pivotal Clinical Trials & Evidence

Jatenzo Phase 3 Pivotal Trial

Study design: Multi-center, randomized, double-blind, placebo-controlled Phase 3 trial (180 days)

Participants: Hypogonadal men

Intervention: Jatenzo 237 mg BID (starting dose), titrated between 158-396 mg BID

Primary endpoint: Percentage of patients achieving average testosterone concentration in normal range (300-1000 ng/dL)

Results:

• 87% of hypogonadal men achieved normal testosterone range at end of treatment
• 87.4% achieved 24-hour average testosterone within reference range following titration

Safety: Well-tolerated with adverse events typical of testosterone therapy

Kyzatrex Phase 3 Single-Arm Trial

Study design: Phase III, single-arm, 6-month trial

Participants: 153 hypogonadal men

Intervention: Kyzatrex 200 mg BID starting dose, titrated to 100-400 mg BID

Primary endpoint: Percentage achieving eugonadal testosterone levels (300-1000 ng/dL)

Results:

• 87.8% of Kyzatrex-treated participants achieved eugonadal mean plasma testosterone values
• 96.1% of 90-day completers achieved eugonadal levels

Safety: No deaths or treatment-related serious adverse events reported

Two-Year Long-Term Safety and Efficacy Study

Study design: Two-year analysis of oral TU formulation in hypogonadal men

Participants: Hypogonadal men on continuous oral TU therapy

Results:

• Total serum testosterone maintained in eugonadal range (300-1000 ng/dL) with mean values of 617 ± 427 ng/dL
• Improvements in sexual function sustained over 2 years
• No clinically significant changes in liver function tests (ALT, AST, bilirubin)

Liver safety: No evidence of liver toxicity in 2-year study

Oral TU and Fatty Liver Disease

Study finding: After 4 months, men with non-alcoholic fatty liver disease (NAFLD) at baseline achieved ~40% reduction in liver fat when treated with oral TU

Implication: Oral TU not only avoids hepatotoxicity but may improve liver health in patients with metabolic syndrome and NAFLD.

Comparison with Methyltestosterone: Liver Safety

Oral TU was not associated with liver toxicity in long- or short-term studies, a sharp contrast to methyltestosterone, historically associated with potentially serious hepatotoxicity.

Mechanism: Methyltestosterone (17α-alkylated steroid) is hepatotoxic and directly transported to liver through portal vein, while lymphatically delivered oral TU is a non-methylated prodrug that avoids first-pass metabolism.

7. Safety Profile + Black Box Warnings

FDA Black Box Warning: Blood Pressure Elevation

All oral testosterone undecanoate products carry a boxed warning:

Testosterone undecanoate can cause blood pressure increases that can increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death, with greater risk in patients with established cardiovascular disease or risk factors for cardiovascular disease.

Blood pressure data:

• Tlando increased systolic BP by average 4.3 mmHg after 4 months (ABPM)
• In hypertensive patients, systolic BP increased 4.4 mmHg and diastolic BP increased 1.8 mmHg
• Kyzatrex: BP increase less than Jatenzo/Tlando but still carries black box warning

Monitoring requirements:

• Blood pressure should be adequately controlled before initiating therapy
• Check BP approximately 3 weeks after initiating and periodically thereafter
• Treat new-onset hypertension or exacerbations of pre-existing hypertension

Recent FDA Label Changes (2025): Cardiovascular Risk

The FDA updated labels of all testosterone products to reflect cardiovascular safety data:

Changes implemented:

1. Removed cardiovascular black box warning about increased MACE risk (based on TRAVERSE trial data)
2. Retained/added blood pressure increase warnings
3. All testosterone products confirmed to increase blood pressure via ambulatory blood pressure monitoring (ABPM) studies

Common Side Effects

Dermatological:

• Acne: 5-10%
• Oily skin

Endocrine/Metabolic:

• Gynecomastia: 1-3%
• Testicular atrophy (from LH/FSH suppression)

Gastrointestinal:

• Nausea (related to capsule formulation)
• Diarrhea
• Abdominal discomfort

Hematological:

• Polycythemia/erythrocytosis: 3-10% (lower than injectable testosterone)
• Elevated hematocrit

Urogenital:

• PSA elevation
• BPH symptoms
• Reduced sperm count/infertility

Other:

• Headache
• Increased libido
• Mood changes

Serious Adverse Events

Cardiovascular Events

TRAVERSE trial showed testosterone was noninferior to placebo for MACE, but blood pressure elevation remains a concern.

Polycythemia

Men on TRT have 315% greater risk for erythrocytosis. Polycythemia during TRT is independent risk factor for MACE/VTE in first year.

Intervention threshold: Hematocrit ≥54% → interrupt therapy, phlebotomy, restart at lower dose

Liver Safety: No Hepatotoxicity

Safety results showed increased liver function test values are not generally associated with oral TU, and no clinically significant liver toxicities noted in clinical trials.

Contrast with 17α-alkylated androgens:

• Methyltestosterone: Known hepatotoxicity, cholestatic jaundice, peliosis hepatis
• Oral TU: No liver toxicity

8. Formulation Options & Administration

FDA-Approved Brand Formulations

Generic Formulations

No generic oral testosterone undecanoate is currently available in the United States. All three FDA-approved products are brand-name only.

International Formulation: Andriol

Andriol Testocaps:

• Available in over 80 countries
• Never approved in the United States
• Strength: 40 mg capsules
• Dosing: Multiple capsules throughout the day (80-160 mg/day total)

Reasons for non-approval in US:

• Highly influenced by dietary fat, leading to significant intra- and inter-patient variability
• Patients unable to obtain eugonadal testosterone levels or achieve clinically meaningful symptom improvement

Administration Guidelines

Step-by-step procedure:

1. Timing: Take twice daily (BID) - once in morning, once in evening
2. Food requirement: Take with meals containing at least 19g fat
   • Breakfast and dinner are ideal
   • Examples: eggs with avocado, salmon with olive oil, nuts and cheese
3. Swallow whole: Do not chew, crush, or open capsules
4. Consistency: Take at approximately same times daily
5. Missed dose: If missed, take as soon as remembered unless close to next dose (do not double dose)

Dietary fat optimization:

• Minimum 19g fat per meal required for adequate absorption
• 30% fat content produces 2.1-2.4× higher testosterone
• Fat sources: olive oil, avocado, nuts, fatty fish, full-fat dairy, eggs

9. Storage & Stability

Storage Requirements

Room temperature storage: Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F) (USP Controlled Room Temperature)

Andriol Testocaps improvement: Originally required refrigeration; reformulated in early 2000s to allow room temperature storage

Additional requirements:

• Protect from light and moisture
• Store in original container
• Keep out of reach of children
• Discard product after expiration date

Stability

Oral testosterone undecanoate in softgel capsules is stable for the duration of product shelf life (typically 24-36 months) when stored according to labeled conditions.

10. Detailed Regulatory Status (FDA, DEA, WADA, International)

FDA Approval History

DEA Schedule III Classification

Testosterone undecanoate is a Schedule III controlled substance under the Anabolic Steroids Control Act of 1990.

Schedule III criteria:

• Moderate to low potential for physical and psychological dependence
• Medical use accepted in United States

Prescribing restrictions:

• Maximum 5 refills per prescription
• Prescription valid for 6 months after issuance
• Electronic prescribing of controlled substances (EPCS) required
• Prescription Drug Monitoring Program (PDMP) reporting mandatory

WADA Prohibited Status

Testosterone and its derivatives are prohibited at all times by WADA.

Classification: Anabolic agent (S1.1 - Anabolic Androgenic Steroids)

All testosterone esters, including testosterone undecanoate, are prohibited both in-competition and out-of-competition.

Athletic performance impact: Study assessed effect of multiple oral doses of testosterone undecanoate on mood state during intense endurance training, finding potential impact on recovery from physical strain.

Therapeutic Use Exemption (TUE): Athletes with documented hypogonadism can apply for TUE to use testosterone legally in sport.

International Regulations

Andriol international availability:

• Available in over 80 countries worldwide
• First introduced in late 1970s in Europe
• Canada: Prescription required
• European Union: Prescription required across all member states
• Australia: Schedule 4 prescription medicine

US-approved formulations expanding internationally:

• Tlando: Filed for approval in Canada
• Tlando: License agreement for Brazil
• Tlando: Distribution agreement for South Korea

11. Product Cross-Reference (Compounding vs Brand)

Brand Name Products: Cost Comparison

Key finding: Main difference between products is cost. Kyzatrex costs $179 regardless of strength, making it the most affordable oral testosterone option.

Comparison with Other TRT Modalities

Most cost-effective: Injectable testosterone cypionate/enanthate ($30-150/month)

Most affordable oral: Kyzatrex ($150-179/month)

Compounded Oral Testosterone

Oral testosterone undecanoate is not typically available from compounding pharmacies in the United States due to complexity of lymphatic-absorption formulation technology. Compounding pharmacies primarily offer topical testosterone (creams, gels) and injectable testosterone esters.

When to Choose Oral Testosterone Undecanoate

Advantages over injectable:

• No needle phobia
• No injection site reactions
• Rapid reversibility (stops working within days)
• Preferred by patients averse to injections

Advantages over gel:

• No secondary exposure risk (to partners/children)
• No application site skin irritation
• Internal administration (no mess, no transfer concerns)

Disadvantages:

• Twice-daily dosing (vs weekly injection or daily gel)
• Must take with fatty meals
• More expensive (except Kyzatrex)
• Blood pressure elevation risk

12. References & Citations

FDA Labeling and Approval Documents

1. Jatenzo (testosterone undecanoate) FDA label - 2019
2. Jatenzo FDA label - 2025 update
3. Jatenzo NDA Summary Review - FDA
4. Tlando (testosterone undecanoate) FDA label - 2022
5. Tlando FDA Approval Letter - 2022
6. DailyMed - TLANDO
7. DailyMed - JATENZO

Product Approval Announcements

8. Clarus Therapeutics receives FDA approval for JATENZO - March 2019
9. FDA approves oral testosterone capsule - Healio 2019
10. FDA approves TLANDO - PR Newswire March 2022
11. Lipocine announces FDA approval of TLANDO - March 2022

Chemical Structure and Mechanism of Action

12. What is the mechanism of Testosterone Undecanoate? - PatSnap Synapse
13. Newer formulations of oral testosterone undecanoate - Oxford Academic 2024
14. Testosterone Undecanoate overview - ScienceDirect
15. Testosterone undecanoate - DrugBank
16. Andriol oral TRT lymphatic absorption - OnlyTest

Pharmacokinetics Studies

17. Pharmacokinetics of testosterone - Wikipedia
18. Reexamination of pharmacokinetics of oral TU - PMC
19. Important effect of food on bioavailability - PubMed
20. Dietary fat modulates testosterone pharmacokinetics - PMC
21. Safety, efficacy, pharmacokinetics of oral TU - Wiley 2025
22. Safety, efficacy, pharmacokinetics - PMC 2025

Clinical Trials and Efficacy

23. Phase III trial of oral testosterone undecanoate - PMC
24. Phase III single-arm 6-month trial - SAGE Journals
25. Two-year analysis of oral TU formulation - PubMed
26. New oral TU formulation restores testosterone - PMC
27. New oral TU formulation - Oxford Academic
28. Real-world experience with Jatenzo - ScienceDirect

Liver Safety Studies

29. Newer formulations and liver side effects - PubMed
30. Study finds oral TU effective with no liver toxicity - Endocrine Society
31. Oral testosterone safe, effective - Healio 2021
32. Is oral testosterone liver toxic? - Maximus
33. Novel oral testosterone shows liver health benefits - Urology Times
34. Safety analysis after 2 years - PMC
35. New oral TU therapy comes of age - PMC

Cardiovascular Safety and Blood Pressure

36. Cardiovascular Safety of TRT - NEJM (TRAVERSE)
37. FDA side effects update: testosterone and blood pressure - MedShadow
38. In Brief: Label changes for testosterone - The Medical Letter
39. Physicians welcome testosterone labeling changes - Medscape 2025

Comparative Reviews

40. Treatment of male hypogonadism with new oral therapies - MDPI
41. Safety aspects of testosterone undecanoate - PMC
42. Evolving role of novel oral agents - Liebertpub
43. Testosterone replacement therapy narrative review - PMC

Andriol History

44. Testosterone undecanoate - Wikipedia
45. Andriol Testocaps: effect of food composition - Wiley
46. Andriol profile - Steroidal

Dosing and Clinical Guidelines

47. JATENZO prescribing information PDF
48. JATENZO dosing and titration - HCP website
49. JATENZO switching guide
50. Clinical experience with Jatenzo: first 50 patients - ScienceDirect

Drug Interactions

51. DailyMed - UNDECATREX
52. Drug interactions between testosterone and warfarin
53. Testosterone replacement and hypoglycemia risk - PMC
54. Drug interactions between insulin and testosterone

Cost and Pricing Comparisons

55. Oral testosterone replacement: Kyzatrex vs Jatenzo - Marley Drug
56. Oral testosterone vs injections - Hone Health
57. Testosterone replacement therapy cost - Hone Health
58. How much does testosterone cost? - SingleCare

Dietary Fat and Absorption

59. Effect of omega-3 and oral TU on testosterone levels
60. DHA supplementation increases testosterone - PubMed

Regulatory Information

61. DEA Drug Scheduling
62. DEA Controlled Substance Schedules
63. Senator Markey calls on Biden admin to lift barriers to testosterone
64. WADA Prohibited List
65. List of drugs banned by WADA - Wikipedia
66. Testosterone and doping control - PMC

Product Information

67. Jatenzo (testosterone undecanoate) - RxList
68. Jatenzo FDA Approval History - Drugs.com
69. Tlando FDA Approval History - Drugs.com
70. Kyzatrex: uses, side effects, dosage - GoodRx

13. Monitoring & Lab Values

Pre-Treatment Baseline Testing

Required before initiating oral testosterone undecanoate:

1. Serum testosterone (total):

   • Two morning samples (7-11 AM) on separate days
   • Diagnosis threshold: <300 ng/dL
   • Confirms hypogonadism diagnosis

2. Complete blood count (CBC):

   • Baseline hemoglobin: Normal 13.5-17.5 g/dL
   • Baseline hematocrit: Normal 38-50%
   • Identifies pre-existing polycythemia

3. Prostate-specific antigen (PSA):

   • Baseline PSA (men ≥40 years)
   • Normal: <4.0 ng/mL
   • Abnormal PSA requires urology evaluation before TRT

4. Digital rectal exam (DRE):

   • Men ≥40 years
   • Assess for prostate abnormalities

5. Blood pressure:

   • Must be adequately controlled before initiating therapy (critical for oral TU due to BP elevation risk)

6. Lipid panel:

   • Total cholesterol, LDL, HDL, triglycerides

7. Liver function tests:

   • ALT, AST, bilirubin (baseline for comparison, though hepatotoxicity not expected)

On-Treatment Monitoring Schedule

Testosterone Levels

Jatenzo-specific monitoring:

• Measure testosterone 6 hours after morning dose at Day 7 and Day 14
• Wait 7 days after starting or adjusting dose before checking levels
• Measure in plain tubes, clotted at room temperature for 30 minutes before centrifugation

Target testosterone: 300-1000 ng/dL (eugonadal range)

Long-term monitoring: Testosterone levels every 6-12 months once stable

Blood Pressure Monitoring (CRITICAL)

Frequency:

• Check BP approximately 3 weeks after initiating
• Periodically thereafter (every 3-6 months minimum)
• More frequently if hypertension or cardiovascular risk factors present

Action thresholds:

• New-onset hypertension or exacerbation of pre-existing hypertension should be treated
• Consider dose reduction or discontinuation if BP uncontrollable

Rationale: Black box warning for blood pressure increases with oral TU

Hematocrit Monitoring

Frequency:

• Baseline, then every 3 months for first year
• Every 6-12 months thereafter if stable

Action thresholds:

• Hematocrit 50-54%: Monitor more frequently, consider dose reduction
• Hematocrit ≥54%: INTERRUPT therapy, phlebotomy, restart at lower dose when normalized

Rationale: Polycythemia increases MACE/VTE risk 5-fold

Prostate Monitoring

PSA:

• Baseline, then 3-6 months after starting, then annually
• Concerning changes: PSA >1.4 ng/mL increase in first year, PSA >4.0 ng/mL

DRE: Annually in men ≥40 years

Liver Function Tests

• 6-12 months, then annually
• No clinically significant liver toxicity expected with oral TU
• Monitoring confirms safety

Lipid Panel

• 6-12 months after starting, then annually
• Testosterone may alter lipid profile

Symptoms Monitoring

Patient-reported outcomes:

• Libido, erectile function (IIEF-5, SHIM questionnaires)
• Energy levels, mood, well-being
• Muscle mass and strength

Adverse event screening:

• Gynecomastia, nipple tenderness
• Acne or oily skin
• Sleep apnea symptoms
• Lower urinary tract symptoms (LUTS)
• Edema
• Gastrointestinal symptoms (nausea, diarrhea)

14. Drug Interactions & Contraindications

Major Drug Interactions

Oral Anticoagulants (Warfarin)

Interaction mechanism: Changes in anticoagulant activity may occur with androgens; testosterone may enhance anticoagulant effect, increasing bleeding risk.

Monitoring:

• More frequent INR and prothrombin time monitoring, especially during initiation/termination of TRT
• Warfarin dose adjustment may be required

Clinical significance: HIGH

Insulin and Oral Hypoglycemics

Interaction mechanism: In diabetic patients, metabolic effects of androgens may decrease blood glucose, necessitating dose reduction of anti-diabetic medication.

Testosterone may increase risk of hypoglycemia.

Monitoring:

• Frequent blood glucose monitoring
• Patients with diabetes should be monitored more closely during TRT
• Insulin/oral hypoglycemic dose may need reduction

Clinical significance: MODERATE to HIGH

Absolute Contraindications

Oral testosterone undecanoate is contraindicated in:

1. Men with breast cancer or known/suspected prostate cancer

   • All TU products carry this contraindication
   • Testosterone may stimulate growth of androgen-responsive tumors

2. Hypersensitivity to testosterone undecanoate or any formulation ingredients

   • Includes castor oil allergy

3. Hypogonadal conditions not associated with structural or genetic etiologies

   • Oral TU not indicated for age-related low testosterone without organic cause

Relative Contraindications (Use with Caution)

Uncontrolled hypertension:

• Blood pressure must be adequately controlled before initiating
• Oral TU causes blood pressure elevation (black box warning)

Severe heart failure (NYHA Class III-IV):

• Fluid retention risk
• Increased cardiovascular workload

Benign prostatic hyperplasia (BPH) with severe symptoms:

• Testosterone may worsen urinary obstruction

Severe sleep apnea:

• Testosterone may exacerbate sleep apnea

Polycythemia (hematocrit >50%):

• Pre-existing polycythemia must be resolved before TRT

Special Populations

Pediatric Use

• Not indicated for use in pediatric populations
• Risk of premature epiphyseal closure
• Risk of virilization

Geriatric Use (≥65 years)

• Increased cardiovascular and prostate cancer risk
• Start at lower doses
• More frequent monitoring required

Renal Impairment

• No dose adjustment required (testosterone metabolized hepatically)

Hepatic Impairment

• Use with caution (though hepatotoxicity not expected with oral TU)
• Monitor liver function tests

Conclusion

Oral testosterone undecanoate represents a paradigm shift in testosterone replacement therapy, being the first oral testosterone approved by the FDA in over 60 years that avoids hepatotoxicity. Through lymphatic absorption that bypasses first-pass hepatic metabolism, oral TU delivers physiological testosterone levels with no liver toxicity, a stark contrast to the hepatotoxic 17α-alkylated oral androgens of the past.

The three FDA-approved formulations—Jatenzo, Tlando, and Kyzatrex—achieve 87-96% efficacy in restoring eugonadal testosterone levels, with sustained benefits over 2 years including improvements in sexual function and potential liver health benefits in patients with NAFLD.

However, the FDA black box warning for blood pressure elevation remains a critical safety concern requiring careful monitoring. The requirement for twice-daily dosing with fatty meals and cost considerations (Kyzatrex $150-179/month vs Jatenzo $900-2400/month) must be balanced against the advantages of oral administration, rapid reversibility, and freedom from injection or transfer concerns.

Oral testosterone undecanoate offers a valuable option for patients who prefer non-injectable therapy, particularly when cost is manageable (Kyzatrex) and blood pressure is well-controlled.

Document Prepared By: Research Team, Epiq Aminos Date: December 2024 Total Word Count: ~13,500 words Total Citations: 70 references